This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Development of orphan products and the impact of the EU Paediatric Regulation, TOPRA Vol 9, No.10
Published on: Oct 15, 2012
Development of orphan medicinal products (OMPs) is challenging by nature: knowledge is usually limited; the patient population are small and often frail; and the implementation of the Paediatric Regulation in the EU has added a layer of complexity, especially for OMPs.
Marie Deneux, Séverine Marconi, David Uguen
2012 – Regulatory Rapporteur